CellCentric Companies
CellCentricвАЩs primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Technology:
Advanced and Next Generation Therapies (Various)
Headquarters:
Cambridge, Cambridgeshire, United Kingdom
Founded Date:
2003
Number Of Exists:
Venture - Series Unknown
Employee Number:
1-10
Industry:
Healthcare Innovations